Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019

Business Wire August 1, 2019

BioTime Announces Name Change to Lineage Cell Therapeutics

Business Wire July 31, 2019

BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System

Business Wire July 11, 2019

BioTime Conducts Sale of Shares in OncoCyte Corporation

Business Wire July 2, 2019

BioTime Announces Appointment of General Counsel

Business Wire May 22, 2019

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

Business Wire May 10, 2019

BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

Business Wire May 9, 2019

BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

Business Wire May 6, 2019

BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

Business Wire May 3, 2019

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

Business Wire May 2, 2019

BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference

Business Wire April 26, 2019

BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

Business Wire April 16, 2019

BioTime, Inc. to Host Earnings Call

Accesswire March 15, 2018

AgeX Therapeutics Closes $10 Million Capital Raise

Business Wire August 17, 2017

BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD

Business Wire August 14, 2017

AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival

Business Wire August 9, 2017

BioTime Reports Second Quarter Results and Recent Corporate Accomplishments

Business Wire August 2, 2017

Investor Network: BIOTIME INC to Host Earnings Call

Accesswire August 2, 2017

AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations

Business Wire August 2, 2017

BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US

Business Wire July 25, 2017